## Vincenzo Santinelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/413923/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brugada syndrome genetics is associated with phenotype severity. European Heart Journal, 2021, 42, 1082-1090.	2.2	59
2	Brugada Syndrome: New Insights From Cardiac Magnetic Resonance and Electroanatomical Imaging. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010004.	4.8	7
3	New electromechanical substrate abnormalities in high-risk patients with Brugada syndrome. Heart Rhythm, 2020, 17, 637-645.	0.7	26
4	Assessing the Malignant Ventricular Arrhythmic Substrate in Patients With Brugada Syndrome. Journal of the American College of Cardiology, 2018, 71, 1631-1646.	2.8	68
5	Clinical Outcome of Electrophysiologically Guided Ablation for Nonparoxysmal Atrial Fibrillation Using a Novel Real-Time 3-Dimensional Mapping Technique. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005904.	4.8	21
6	Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome. Circulation: Arrhythmia and Electrophysiology, 2017, 10, e005053.	4.8	177
7	Response to Letter Regarding Article, "Wolff-Parkinson-White Syndrome in the Era of Catheter Ablation: Insights From a Registry Study of 2169 Patients― Circulation, 2015, 131, e499.	1.6	Ο
8	The natural history of WPW syndrome. European Heart Journal Supplements, 2015, 17, A8-A11.	0.1	2
9	Multipoint Left Ventricular Pacing in a Single Coronary Sinus Branch Improves Midâ€Term Echocardiographic and Clinical Response to Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2015, 26, 58-63.	1.7	50
10	Brugada Syndrome Phenotype Elimination by Epicardial Substrate Ablation. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 1373-1381.	4.8	210
11	Electrophysiology Testing and Catheter Ablation Are Helpful When Evaluating Asymptomatic Patients with Wolff-Parkinson-White Pattern. Cardiac Electrophysiology Clinics, 2015, 7, 371-376.	1.7	2
12	Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. Europace, 2015, 17, 1518-1525.	1.7	56
13	Wolff-Parkinson-White Syndrome in the Era of Catheter Ablation. Circulation, 2014, 130, 811-819.	1.6	169
14	Risk of Malignant Arrhythmias in Initially Symptomatic Patients With Wolff-Parkinson-White Syndrome. Circulation, 2012, 125, 661-668.	1.6	96
15	Atrial Fibrillation Ablation. Revista Espanola De Cardiologia (English Ed ), 2012, 65, 560-569.	0.6	4
16	Asymptomatic Wolff-Parkinson-White Syndrome Should be Ablated. Cardiac Electrophysiology Clinics, 2012, 4, 281-285.	1.7	2
17	Irrigated-tip magnetic catheter ablation of AF: A long-term prospective study in 130 patients. Heart Rhythm, 2011, 8, 8-15.	0.7	41
18	Device-Based Left Atrial Appendage Closure. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 418-419.	4.8	1

#	Article	IF	CITATIONS
19	Radiofrequency Catheter Ablation and Antiarrhythmic Drug Therapy. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 808-814.	4.8	105
20	Catheter ablation versus antiarrhythmic drug therapy for the treatment of atrial fibrillation: past, present and future. Journal of Cardiovascular Medicine, 2010, 11, 404-405.	1.5	1
21	Asymptomatic Ventricular Preexcitation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 102-107.	4.8	71
22	New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significance. European Heart Journal, 2009, 30, 2985-2992.	2.2	60
23	The Natural History of Asymptomatic Ventricular Pre-Excitation. Journal of the American College of Cardiology, 2009, 53, 275-280.	2.8	184
24	Pulmonary vein isolation after circumferential pulmonary vein ablation: Comparison between Lasso and three-dimensional electroanatomical assessment of complete electrical disconnection. Heart Rhythm, 2009, 6, 1706-1713.	0.7	27
25	Safety and Efficacy of Remote Magnetic Ablation for Atrial Fibrillation. Journal of the American College of Cardiology, 2008, 51, 1614-1615.	2.8	11
26	Atrial fibrillation progression and management: A 5-year prospective follow-up study. Heart Rhythm, 2008, 5, 1501-1507.	0.7	109
27	Remote ablation of accessory pathways. European Heart Journal, 2008, 29, 422-422.	2.2	3
28	Sudden Death and Ventricular Preexcitation: Is it Necessary to Treat the Asymptomatic Patients?. Current Pharmaceutical Design, 2008, 14, 762-765.	1.9	12
29	Non-fluoroscopic mapping as a guide for atrial ablation: current status and expectations for the future. Country Review Ukraine, 2007, 9, 136-147.	0.8	6
30	Robotic and magnetic navigation for atrial fibrillation ablation. How and why?. Expert Review of Medical Devices, 2007, 4, 885-894.	2.8	11
31	Remote Navigation and Ablation of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2007, 18, S18-S20.	1.7	17
32	Mapping and ablation: A worldwide perspective. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 195-198.	1.3	2
33	Multielectrode basket catheter: A new tool for curing atrial fibrillation?. Heart Rhythm, 2006, 3, 385-386.	0.7	11
34	How to perform encircling ablation of the left atrium. Heart Rhythm, 2006, 3, 1105-1109.	0.7	27
35	Endocardial impedance mapping during circumferential pulmonary vein ablation of atrial fibrillation differentiates between atrial and venous tissue. Heart Rhythm, 2006, 3, 171-178.	0.7	24
36	Robotic Magnetic Navigation for Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2006, 47, 1390-1400.	2.8	369

#	Article	IF	CITATIONS
37	A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial Fibrillation. Journal of the American College of Cardiology, 2006, 48, 2340-2347.	2.8	623
38	Substrate Ablation in Treatment of Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2006, 17, S23-S27.	1.7	8
39	Ablation of atrial fibrillation. Current Cardiology Reports, 2006, 8, 343-346.	2.9	7
40	Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation. New England Journal of Medicine, 2006, 354, 934-941.	27.0	898
41	Atrial Fibrillation Ablation: State of the Art. American Journal of Cardiology, 2005, 96, 59-64.	1.6	106
42	Atrial fibrillation ablation: a realistic alternative to pharmacologic therapy. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 608-609.	3.3	8
43	Towards a unified strategy for atrial fibrillation ablation?. European Heart Journal, 2005, 26, 1687-1688.	2.2	8
44	Transcatheter radiofrequency ablation of atrial fibrillation in patients with mitral valve prostheses and enlarged atria. Journal of the American College of Cardiology, 2005, 45, 868-872.	2.8	61
45	Atrio-Esophageal Fistula as a Complication of Percutaneous Transcatheter Ablation of Atrial Fibrillation. Circulation, 2004, 109, 2724-2726.	1.6	853
46	Radiofrequency Ablation in Children with Asymptomatic Wolff–Parkinson–White Syndrome. New England Journal of Medicine, 2004, 351, 1197-1205.	27.0	198
47	Prevention of latrogenic Atrial Tachycardia After Ablation of Atrial Fibrillation. Circulation, 2004, 110, 3036-3042.	1.6	340
48	First Human Chronic Experience with Cardiac Contractility Modulation by Nonexcitatory Electrical Currents for Treating Systolic Heart Failure:. Journal of Cardiovascular Electrophysiology, 2004, 15, 418-427.	1.7	85
49	Prevention of Atrial Fibrillation:. Journal of Cardiovascular Electrophysiology, 2004, 15, 1118-1119.	1.7	5
50	The Who, What, Why, and How‶o Guide for Circumferential Pulmonary Vein Ablation. Journal of Cardiovascular Electrophysiology, 2004, 15, 1226-1230.	1.7	80
51	Pulmonary Vein Denervation Enhances Long-Term Benefit After Circumferential Ablation for Paroxysmal Atrial Fibrillation. Circulation, 2004, 109, 327-334.	1.6	941
52	Segmental pulmonary vein isolation versus the circumferential approach: Is the tide turning?. Heart Rhythm, 2004, 1, 326-328.	0.7	7
53	Left atrial tachycardia after circumferential pulmonary vein ablation for atrial fibrillation. Journal of the American College of Cardiology, 2004, 44, 1071-1079.	2.8	221
54	Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern. Journal of the American College of Cardiology, 2003, 41, 239-244.	2.8	236

#	Article	IF	CITATIONS
55	Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation. Journal of the American College of Cardiology, 2003, 42, 185-197.	2.8	768
56	A Randomized Study of Prophylactic Catheter Ablation in Asymptomatic Patients with the Wolff–Parkinson–White Syndrome. New England Journal of Medicine, 2003, 349, 1803-1811.	27.0	216
57	Atrial Electroanatomic Remodeling After Circumferential Radiofrequency Pulmonary Vein Ablation. Circulation, 2001, 104, 2539-2544.	1.6	848
58	Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia. Circulation, 2000, 102, 2619-2628.	1.6	1,312
59	Silent myocardial ischemia. American Heart Journal, 1996, 131, 1239.	2.7	0
60	Causal relation between silent myocardial ischemia and sudden death. American Heart Journal, 1994, 128, 816-820.	2.7	6
61	Effects of Flecainide and Propafenone on Systolic Performance in Subjects with Normal Cardiac Function. Chest, 1993, 103, 1068-1073.	0.8	20
62	Propafenone in Wolff-Parkinson-White syndrome at risk. Cardiovascular Drugs and Therapy, 1990, 4, 681-685.	2.6	4
63	Are ioxaglate and iopamidol equally safe and well tolerated in cardiac angiography? A randomized, double-blind clinical study. American Heart Journal, 1990, 120, 1130-1136.	2.7	1
64	Paroxysmal Supraventricular Tachycardia: Experience with Propafenone. Angiology, 1989, 40, 563-568.	1.8	6
65	Incremental Biorate Control Ventricular Pacing and Ventricular Arrhythmogenicity. PACE - Pacing and Clinical Electrophysiology, 1986, 9, 251-252.	1.2	0
66	LETTERS TO THE EDITOR. PACE - Pacing and Clinical Electrophysiology, 1984, 7, 1088-1089.	1.2	0
67	Ventricular tachyarrhythmias complicating the idiopathic or acquired long QT syndrome: A reentry in the his-purkinje system?. Journal of Electrocardiology, 1984, 17, 103.	0.9	0
68	Sick sinus syndrome: the role of hypervagotonia. International Journal of Cardiology, 1984, 5, 532-535.	1.7	11
69	Ventricular tachyarrhythmias complicating amiodarone therapy in the presence of hypokalemia. American Journal of Cardiology, 1984, 53, 1462-1463.	1.6	21
70	Amiodarone-induced ventricular tachyarrhythmias. American Heart Journal, 1984, 107, 610-611.	2.7	7
71	Atrial parasystole and amiodarone. American Heart Journal, 1984, 108, 1029-1031.	2.7	2
72	Exit Block during "Common―Atrial Flutter: Convincing Proof for Focal Origin of the Arrhythmia. Chest, 1984, 85, 144.	0.8	0

#	Article	IF	CITATIONS
73	Junctional Ectopic Tachycardia and Verapamil. Chest, 1984, 85, 121-122.	0.8	4
74	ST Segment Alternans in Vasospatic Angina. PACE - Pacing and Clinical Electrophysiology, 1983, 6, 979-980.	1.2	2
75	His Purkinje System Conduction and Ventricular Fibrillation in Man. PACE - Pacing and Clinical Electrophysiology, 1983, 6, 1358-1358.	1.2	1
76	Mexiletine for treatment of sustained recurrent ventricular tachycardia. International Journal of Cardiology, 1983, 2, 443-445.	1.7	1
77	Heart rate acceleration without changes in the QT interval and severe ventricular tachyarrhythmias: a variant of the long QT syndrome?. International Journal of Cardiology, 1983, 4, 69-71.	1.7	2
78	Rapid increase of intraventricular conduction delay in the genesis of ventricular fibrillation after atropine. International Journal of Cardiology, 1983, 3, 109-111.	1.7	3
79	Electrophysiologic actions of amiodarone. American Heart Journal, 1983, 105, 520.	2.7	3
80	Intravenous mexiletine in management of lidocaine-resistant ventricular tachycardia. American Heart Journal, 1983, 105, 680-685.	2.7	19
81	Electrophysiologic effects of amiodarone. American Heart Journal, 1983, 106, 1170.	2.7	2
82	Further Observations on the Electrophysiologic Effects of Oral Amiodarone Therapy. Chest, 1982, 82, 117-120.	0.8	12